Hematopoietic stem cell transplantation using single UM171-expanded cord blood
                         CML - Chronic myeloid leukemia

                                                                                                                                       Français
''Benefits of cord blood transplantation include low rates of relapse and chronic graft-versus-host disease (GVHD). However, the use of cord blood is rapidly declining because of the high incidence of infections, severe acute GVHD, and transplant-related mortality. UM171, a haematopoietic stem cell self-renewal agonist, has been s​hown to expand cord blood stem cells and enhance multilineage blood cell reconstitution in mice. We aimed to investigate the safety and feasibility of single UM171-expanded cord blood transplantation in patients with haematological malignancies who do not have a suitable HLA-matched donor.''
​Extract of  Hematopoietic stem cell transplantation using single UM171-expanded cord blood: a single-arm, phase 1–2 safety and feasibility study
"In their new study, the IRIC researchers found to their great surprise that UM171 is able to act as a veritable “fountain of youth” for blood stem cells. Three days after administration of the molecule, the stem cells presented an epigenome similar to the initial young cord-blood cells, whereas in the absence of UM171, these cells underwent premature epigenome aging.
As a result, patients transplanted with the rejuvenated cells very quickly experience an overall improvement in their quality of life as their blood cell counts are rapidly recovered. Not only does UM171 rejuvenate the cells, they also become more competent at producing an improved immune system. As a result, after six months, most patients no longer need immunosuppressants, normally needed to reverse the negative immunological impact of bone-marrow transplants."
Extract of UM171: the molecule that keeps on giving

CLINICAL TRIALS

US Study of UM171-Expanded CB in Patients With High Risk Leukemia/Myelodysplasia
Fred Hutchinson / University of Washington Cancer Consortium
Seattle, Washington, United States

Expanded Cord Blood in Patients in Need of an Allogeneic Stem Cell Transplant
​Hopital Maisonneuve-Rosemont
Montreal, Quebec, Canada
                           More clinical trials for UM171
ARTICLES
 
​
Treatment Optimization Efforts Seek to Overcome Resistance in Advanced CML
April 15, 2022, OncLive

Cord-Blood Engraftment Using an Enhanced Dual-Conditioning Regimen for Malignant Hematologic Diseases
January 25, 2022 , Sage Journals

Cord blood expansion has arrived
October 21, 2021, Blood         
    
AABB NEWS: DREAMS OF EXPANSION
July 20, 2021, AABB

Evaluation of a clinical-grade, cryopreserved, ex vivo-expanded stem cell product from cryopreserved primary umbilical cord blood demonstrates multilineage hematopoietic engraftment in mouse xenografts
May 19, 2021, Cytotherapy

Cord Blood Transplantation: State of the Science
March 2021, Cord Blood Association

UM171: the molecule that keeps on giving
January 12, 2021,  Udem Nouvelles

UM171 Preserves Epigenetic Marks that Are Reduced in Ex Vivo Culture of Human HSCs via Potentiation of the CLR3-KBTBD4 Complex
January 7, 2021, PubMed

Lysine-specific demethylase 1A restricts ex vivo propagation of human HSCs and is a target of UM171
November 5, 2020, Blood

Blood cancer: World premiere at Hôpital Maisonneuve-Rosemont
October 8, 2020, FHMR

Hematopoietic stem cell transplantation using single UM171-expanded cord blood
October 3, 2020, ASTCT

Umbilical Cord Blood Transplants: Current Status and Evolving Therapies
October 2, 2020, Frontiers in Pediatrics

Autoimmune disease: UM171 saves another life
September 30, 2020,  Science Daily

Single UM171‐Expanded Cord Blood Transplants Support Robust T‐Cell Reconstitution with Low Rates of Severe Infections
September 9, 2020, Stem Cells

Single UM171-expanded cord blood transplant can cure severe idiopathic aplastic anemia in absence of suitable donors
August 4, 2020, European Journal of Haematology

UM171 induces a homeostatic inflammatory-detoxification response supporting human HSC self-renewal
November 8, 2019, Plos One

Hematopoietic stem cell transplantation using single UM171-expanded cord blood: a single-arm, phase 1–2 safety and feasibility study
November 6, 2019, The Lancet Heamatology

Blood cancers: New generation stem cell transplant significantly reduces complications for patients
November 5, 2019, Université of Montreal

UM171 expands distinct types of myeloid and NK progenitors from human pluripotent stem cells
April 29, 2019, Nature.com

UM171 Molecule: Completion of Phase I/II clinical trial for the treatment of blood cancer patients
June 27, 2018, IRIC

Researchers develop molecule that boosts cord blood stem cells
September 18, 2014, CTV news


​                                               See also Cure possible  for CML?